Sabra Healthcare REIT (NASDAQ:SBRA – Get Free Report) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect Sabra Healthcare REIT to post earnings of $0.39 per share and revenue of $201.9650 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 13, 2026 at 2:00 PM ET.
Sabra Healthcare REIT Stock Up 0.3%
NASDAQ SBRA opened at $19.15 on Wednesday. The stock has a market capitalization of $4.78 billion, a P/E ratio of 26.60 and a beta of 0.67. Sabra Healthcare REIT has a 52 week low of $15.60 and a 52 week high of $19.97. The company has a debt-to-equity ratio of 0.92, a quick ratio of 5.19 and a current ratio of 5.19. The stock has a fifty day moving average of $18.99 and a 200-day moving average of $18.73.
Sabra Healthcare REIT Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 27th. Investors of record on Friday, February 13th will be given a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date is Friday, February 13th. Sabra Healthcare REIT’s dividend payout ratio (DPR) is presently 166.67%.
Institutional Investors Weigh In On Sabra Healthcare REIT
Analysts Set New Price Targets
SBRA has been the topic of a number of research reports. Truist Financial upped their target price on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Tuesday, January 20th. National Bankshares set a $22.00 price objective on shares of Sabra Healthcare REIT in a report on Friday, October 17th. UBS Group initiated coverage on shares of Sabra Healthcare REIT in a report on Tuesday, November 18th. They set a “neutral” rating and a $20.00 target price for the company. Jefferies Financial Group reiterated a “buy” rating and set a $22.00 target price on shares of Sabra Healthcare REIT in a research report on Monday, December 15th. Finally, Wells Fargo & Company raised their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 25th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Sabra Healthcare REIT has an average rating of “Hold” and a consensus price target of $21.11.
Read Our Latest Analysis on Sabra Healthcare REIT
About Sabra Healthcare REIT
Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.
Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.
See Also
- Five stocks we like better than Sabra Healthcare REIT
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Sabra Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
